Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(2):146–149. doi: 10.1038/bjc.1997.355

Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.

S Marchini 1, A M Codegoni 1, C Bonazzi 1, S Chiari 1, M Broggini 1
PMCID: PMC2223926  PMID: 9231912

Abstract

The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.

Full text

PDF
146

Images in this article

147Figure 1
on p.147
147Figure 2
on p.147
148Figure 3
on p.148
148Figure 4
on p.148

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beijersbergen R. L., Bernards R. Cell cycle regulation by the retinoblastoma family of growth inhibitory proteins. Biochim Biophys Acta. 1996 Jun 7;1287(2-3):103–120. doi: 10.1016/0304-419x(96)00002-9. [DOI] [PubMed] [Google Scholar]
  2. Cairns P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., van der Riet P., Blaugrund J. E., Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science. 1994 Jul 15;265(5170):415–417. doi: 10.1126/science.8023167. [DOI] [PubMed] [Google Scholar]
  3. Campbell I. G., Foulkes W. D., Beynon G., Davis M., Englefield P. LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer. 1995 Oct 9;63(2):222–225. doi: 10.1002/ijc.2910630213. [DOI] [PubMed] [Google Scholar]
  4. Devlin J., Elder P. A., Gabra H., Steel C. M., Knowles M. A. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci. Br J Cancer. 1996 Feb;73(4):420–423. doi: 10.1038/bjc.1996.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. He J., Allen J. R., Collins V. P., Allalunis-Turner M. J., Godbout R., Day R. S., 3rd, James C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 1994 Nov 15;54(22):5804–5807. [PubMed] [Google Scholar]
  6. Jin X., Nguyen D., Zhang W. W., Kyritsis A. P., Roth J. A. Cell cycle arrest and inhibition of tumor cell proliferation by the p16INK4 gene mediated by an adenovirus vector. Cancer Res. 1995 Aug 1;55(15):3250–3253. [PubMed] [Google Scholar]
  7. Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harshman K., Tavtigian S. V., Stockert E., Day R. S., 3rd, Johnson B. E., Skolnick M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994 Apr 15;264(5157):436–440. doi: 10.1126/science.8153634. [DOI] [PubMed] [Google Scholar]
  8. Kawamata N., Morosetti R., Miller C. W., Park D., Spirin K. S., Nakamaki T., Takeuchi S., Hatta Y., Simpson J., Wilcyznski S. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies. Cancer Res. 1995 Jun 1;55(11):2266–2269. [PubMed] [Google Scholar]
  9. Li R., Hannon G. J., Beach D., Stillman B. Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. Curr Biol. 1996 Feb 1;6(2):189–199. doi: 10.1016/s0960-9822(02)00452-9. [DOI] [PubMed] [Google Scholar]
  10. Maestro R., Boiocchi M. Sunlight and melanoma: an answer from MTS1 (p16) Science. 1995 Jan 6;267(5194):15–16. doi: 10.1126/science.7809600. [DOI] [PubMed] [Google Scholar]
  11. Merlo A., Herman J. G., Mao L., Lee D. J., Gabrielson E., Burger P. C., Baylin S. B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995 Jul;1(7):686–692. doi: 10.1038/nm0795-686. [DOI] [PubMed] [Google Scholar]
  12. Nishikawa R., Furnari F. B., Lin H., Arap W., Berger M. S., Cavenee W. K., Su Huang H. J. Loss of P16INK4 expression is frequent in high grade gliomas. Cancer Res. 1995 May 1;55(9):1941–1945. [PubMed] [Google Scholar]
  13. Nobori T., Miura K., Wu D. J., Lois A., Takabayashi K., Carson D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994 Apr 21;368(6473):753–756. doi: 10.1038/368753a0. [DOI] [PubMed] [Google Scholar]
  14. Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11045–11049. doi: 10.1073/pnas.91.23.11045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pines J. Cyclins and cyclin-dependent kinases: theme and variations. Adv Cancer Res. 1995;66:181–212. doi: 10.1016/s0065-230x(08)60254-7. [DOI] [PubMed] [Google Scholar]
  16. Quelle D. E., Ashmun R. A., Hannon G. J., Rehberger P. A., Trono D., Richter K. H., Walker C., Beach D., Sherr C. J., Serrano M. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene. 1995 Aug 17;11(4):635–645. [PubMed] [Google Scholar]
  17. Rodabaugh K. J., Biggs R. B., Qureshi J. A., Barrett A. J., Welch W. R., Bell D. A., Berkowitz R. S., Mok S. C. Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumors. Oncogene. 1995 Oct 5;11(7):1249–1254. [PubMed] [Google Scholar]
  18. Schultz D. C., Vanderveer L., Buetow K. H., Boente M. P., Ozols R. F., Hamilton T. C., Godwin A. K. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res. 1995 May 15;55(10):2150–2157. [PubMed] [Google Scholar]
  19. Sheaff R. J., Roberts J. M. Tumor suppression. Lessons in p16 from phylum Falconium. Curr Biol. 1995 Jan 1;5(1):28–31. doi: 10.1016/s0960-9822(95)00009-1. [DOI] [PubMed] [Google Scholar]
  20. Sherr C. J. G1 phase progression: cycling on cue. Cell. 1994 Nov 18;79(4):551–555. doi: 10.1016/0092-8674(94)90540-1. [DOI] [PubMed] [Google Scholar]
  21. Sherr C. J., Roberts J. M. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995 May 15;9(10):1149–1163. doi: 10.1101/gad.9.10.1149. [DOI] [PubMed] [Google Scholar]
  22. Shiohara M., el-Deiry W. S., Wada M., Nakamaki T., Takeuchi S., Yang R., Chen D. L., Vogelstein B., Koeffler H. P. Absence of WAF1 mutations in a variety of human malignancies. Blood. 1994 Dec 1;84(11):3781–3784. [PubMed] [Google Scholar]
  23. Spruck C. H., 3rd, Gonzalez-Zulueta M., Shibata A., Simoneau A. R., Lin M. F., Gonzales F., Tsai Y. C., Jones P. A. p16 gene in uncultured tumours. Nature. 1994 Jul 21;370(6486):183–184. doi: 10.1038/370183a0. [DOI] [PubMed] [Google Scholar]
  24. Stone S., Jiang P., Dayananth P., Tavtigian S. V., Katcher H., Parry D., Peters G., Kamb A. Complex structure and regulation of the P16 (MTS1) locus. Cancer Res. 1995 Jul 15;55(14):2988–2994. [PubMed] [Google Scholar]
  25. Zhang S. Y., Klein-Szanto A. J., Sauter E. R., Shafarenko M., Mitsunaga S., Nobori T., Carson D. A., Ridge J. A., Goodrow T. L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res. 1994 Oct 1;54(19):5050–5053. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES